Golden State Equity Partners Acquires 646 Shares of AstraZeneca PLC (NASDAQ:AZN)

Golden State Equity Partners increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.1% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 6,455 shares of the company’s stock after purchasing an additional 646 shares during the period. Golden State Equity Partners’ holdings in AstraZeneca were worth $474,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Cibc World Markets Corp increased its holdings in shares of AstraZeneca by 1.1% during the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock worth $845,000 after buying an additional 142 shares in the last quarter. CoreCap Advisors LLC increased its holdings in shares of AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after buying an additional 155 shares in the last quarter. Spinnaker Investment Group LLC increased its holdings in shares of AstraZeneca by 3.1% during the first quarter. Spinnaker Investment Group LLC now owns 5,754 shares of the company’s stock worth $423,000 after buying an additional 174 shares in the last quarter. Tiller Private Wealth Inc. increased its holdings in shares of AstraZeneca by 5.7% during the fourth quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company’s stock worth $219,000 after buying an additional 181 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its holdings in shares of AstraZeneca by 0.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock worth $2,313,000 after buying an additional 189 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ AZN opened at $69.68 on Thursday. The company has a market capitalization of $216.10 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 1.29 and a beta of 0.38. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The stock has a fifty day simple moving average of $70.50 and a 200 day simple moving average of $70.45. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. AstraZeneca’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.06 earnings per share. Sell-side analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas started coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.